BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Non-Infectious Uveitis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Non-Infectious Uveiti
 s\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06258915-8@assetmemo.bio
DTSTAMP:20261122T013012Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Humira (adalimumab): Phase 3 readout est. (NCT06258915)
DESCRIPTION:Humira (adalimumab)\, phase 3\, Non-Infectious Uveitis.\nStudy:
  Treatment FOr Corticosteroid Dependent UveitiS\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ada
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06258915
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
